Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Future treatment landscape for sarcoma

Rimas J. Orentas • 7 Apr 2021
AACR 2021
Sarcoma

Rimas J. Orentas, PhD, Seattle Children’s Research Institute, Seattle, WA, shares his thoughts on how the treatment landscape for sarcoma will evolve over the next few years, highlighting the impacts of epigenetic regulation on treatment and the potential of epigenetic modifiers. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Rimas J. Orentas, PhD, has received research support from Lentigen, a Miltenyi Biotec Company; and has participated in a consultancy role for Umoja Biopharma.

More from Rimas J. Orentas

4:48
CAR-T for Ewing’s sarcoma: impacts of the tumor microenvironment
Rimas J. Orentas • 7 Apr 2021
1:48
FGFR-4-targeted CARs for rhabdomyosarcoma
Rimas J. Orentas • 7 Apr 2021

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadezhda Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadezhda Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals